This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • Septo-optic dysplasia – a case note review

Septo-optic dysplasia – a case note review
Reviewed by Claire Howard

2 August 2024 | Claire Howard | EYE - Neuro-ophthalmology
Share This

Septo-optic dysplasia (SOD) is a congenital disorder belonging to the midline brain malformation group. The condition manifests as a classical triad, including optic nerve hypoplasia (ONH), agenesis of midline structures (absent septum pel-lucidum and agenesis of the corpus callosum), and hypoplasia of the hypothalamo-pituitary axis. This retrospective case note review aimed to record the clinical, neuro-radiological, and systemic features of patients with SOD. Its objective was to identify patients with features consistent with SOD over a six-year period, including optic nerve hypoplasia with agenesis of midline structures, along with an absent septum pellucidum and / or agenesis of the corpus callosum. Thirty-three patients were included. Optic nerve hypoplasia (ONH) was bilateral in 81.82% of cases (n=27) and unilateral in 18.18% of cases (n=6), with three cases in each eye. Developmental delay was documented in 24.2% (n=8). The most frequent magnetic resonance imaging features that were consistent with SOD included: isolated absent septum pellucidum reported in 51.51% (n=17); isolated corpus callosum agenesis in 33.33% (n=11); and both absent septum pellucidum and corpus callosum agenesis in 15.15% (n=5). Pituitary gland abnormalities, including pituitary hypoplasia in 9% (n=3) or hypoplasia of pituitary infundibulum in 6% (n=2) were less common. Pituitary hormonal abnormalities were present in 50% of the 10 tested patients (n=5). Although bilateral ONH is more frequent, hypoplasia of just one optic nerve could be a presenting feature of SOD. The authors recommend neuro-imaging and further endocrine work-up in those diagnosed with unilateral and bilateral ONH. A multidisciplinary approach involving the paediatrician, paediatric neurologist, endocrinologist, and genetic teams along with vision rehabilitation team is suggested as beneficial for optimal outcomes.

Septo-optic dysplasia: a case series of 33 patients.
Nalawade R, Bhate M.
NEURO-OPHTHALMOLOGY
2024;48(1):13–8.
Share This
CONTRIBUTOR
Claire Howard

Salford Royal NHS Foundation Trust, Salford, UK.

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency